Obsah souboru
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=windows-1250">
<meta name="Author" content="Josef Berger">
<title>Journal of Applied Biomedicine</title>
</head>
<body>
<style type="text/css">
documentByLine {display: none;}
</style>
<b><font color="#3366FF"><font size=+4>Journal of APPLIED BIOMEDICINE</font></font></b><br>
ISSN 1214-0287 (on-line)<br>
ISSN 1214-021X (printed)
<br><br>
Volume 2 (2004), No 3, p 123-130
<br><br>
<hr WIDTH="100%">
<br><br>
<font size=+2><b>
Alzheimer�s disease: neurobiological advances supporting proposals for new therapeutical approaches
</b></font>
<br><br>
<i>
Andre Nieoullon
</i>
<br><br>
Address: Andre Nieoullon, Cellular Interactions, Neurodegeneration and Neuroplasticity (IC2N) Research Unit
UMR6186-CNRS, l�Universite de la Mediterranee, 31, Chemin Joseph Aiguier, 13402 Marseilles cedex 20,
France
<br>
<a href="mailto:nieoullon@lncf.cnrs-mrs.fr">nieoullon@lncf.cnrs-mrs.fr </a>
<br><br>
Received 21st April 2004.<br>
Revised 6th May 2004.<br>
Published online 4th June 2004.<br>
<br>
<a href="http://www.zsf.jcu.cz/jab/2_3/nieoullon_ad.pdf">Full text article (pdf)</a><br>
<br>
<table cellspacing=2>
<tr>
<td width=80% valign=top align=left>
<a name="summary"><b>SUMMARY</b></a><br>
Alzheimer�s disease is one of the most important diseases related to ageing. The social and human
cost is very high especially because of the increase in the normal life span in developed countries.
There is presently no cure for the disease and stimulating the cholinergic central neurotransmission
is today the only therapeutic approach which has been shown to successfully improve the cognitive
state in a significant population of patients. In such a context, research projects should be aimed
specifically at reducing brain lesions resulting from the disease, especially those due to the amyloid
peptide accumulation, and at reducing or even halting the clinical evolution of the disease and
consequent neurodegenerative processes.
<br><br>
<a name="keywords"><b>KEY WORDS</b></a><br>
Neuroprotection; amyloid protein precursor (APP); �A4 protein; tau protein; astrocytes; excitatory amino acids<br>
<br><br>
<a name="references"><b>REFERENCES</b></a><br>
Allain H., D. Bentue-Ferrer, O. Trubut, S. Gauthier,
B.F. Michel., C. Drieu-La-Rochelle: Alzheimer�s
disease: the pharmacological pathway. Fund.
Clin. Pharmacol. 17:419-428, 2003.<br><br>
Bains J.S. and C.A. Shaw: Neurodegenerative
disorders in humans: the role of glutathione in
oxidative stress-mediated neuronal death. Brain
Res. Rev. 25:335-358, 1997.<br><br>
Bush A.I.: Metal complexing agents as therapies for
Alzheimer�s disease. Neurobiol. Aging 23:1031-1038, 2002.<br><br>
Castro A. and A. Martinez: Inhibition of tau protein
phosphorylation: a new therapeutic strategy for
the treatment of Alzheimer�s disease and other
neurodegenerative disorders. Exp. Opin. Ther.
Patents 10:1519-1527, 2000.<br><br>
Citron M.: Emerging Alzheimer�s disease therapies:
inhibition of beta-secretase. Neurobiol. Aging 23:1017-1022, 2002.<br><br>
Cutler N.R. and J.J. Sramek: Review of the next
generation of Alzheimer�s disease therapeutics: challenges for drug development. Prog. Neuro-
Psychopharmacol. Biol. Psychiat. 25:27-57,
2001.<br><br>
DeFeudis F.V.: Gingko biloba extract (Egb 761).
>From chemistry to the clinic. Ullstein Medical,
Wiesbaden, pp 401, 1998.<br><br>
Doble A.: The role of excitotoxicity in
neurodegenerative disease: implications for
therapy. Pharmacol. Ther. 81:163-221, 1999.<br><br>
Emilien G., K. Beyreuther, C. Masters,
J.M. Maloteaux: Prospects for pharmacological
intervention in Alzheimer�s disease. Arch
Neurol. 57:454-459, 2000.<br><br>
Friedlander R.M.: Mechanism of disease: apoptosis
and caspases in neurodegenerative diseases. N.
Engl. J. Med. 348:1365-1375, 2003.<br><br>
Gandy S.: Molecular basis for anti-amyloid therapy
in the prevention and treatment of Alzheimer�s
disease. Neurobiol. Aging 23:1009-1016, 2002.<br><br>
Gao W.Q., R.J. Well, M. Dugich-Djordjevic: The
therapeutic potentials of neurotrophic factors for
diseases of the nervous system. Expert Opin.
Ther. Patents 7:325-338, 1997.<br><br>
Gasparini F., K. Lingenhohl., N. Stoehr., P.J. Flor,
M. Heinrich, L. Vranesic, M. Biollaz,
H. Allgeier, R. Heckendorn, S. Urwyler,
M.A. Varney, E.C. Johnston, S.D. Hess,
S.P. Rao, A.I. Sacaan., E.M. Santori.,
G. Velicelebi, R. Khun: 2-methyl-6-
(phenylethynyl)-pyridine (MPEP), a potent,
selective and systemically active mGlu5 receptor
antagonist. Neuropharmacology 38:1493-1503,
1999.<br><br>
Had-Aissouni L., D.B. Re, A. Nieoullon,
L. Kerkerian-LeGoff: Importance of astrocytic
inactivation of synaptically released glutamate
for cell survival in the central nervous system -
are astrocytes vulnerable to low intracellular
glutamate concentrations? J. Physiol. (Paris) 96:317-322, 2002.<br><br>
Hock C., U. Konietzko, J.R. Streffer: Antibodies
against beta-amyloid slow cognitive decline in
Alzheimer�s disease. Neuron 38:547-554, 2003.<br><br>
Lesh K.P.: Gene transfert to the brain: emerging
therapeutic strategy in psychiatry? Biol. Psych.
45:247-253, 2002.<br><br>
Nieoullon A.: Bases cellulaires des processus
d�g�n�ratifs. Th�rapie 53: 21-29, 1998.
Re D.B., J. Boucraut, D. Samuel, S. Birman,
L. Kerkerian-LeGoff., L. Had-Aissouni:
Glutamate transport alteration triggers
differentiation-state selective oxidative death of
cultured astrocytes: a mechanism different from
excitotoxicity depending on intracellular GSH
content. J. Neurochem. 85:1159-1170, 2003.<br><br>
Roberts S.B: gamma-secretase inhibitors and
Alzheimer�s disease. Adv. Drug Delivery Rev.
54: 1579-1588, 2002.
Rothstein J.D., G. Dykes-Hoberg, C.A. Pardo,
L.A. Bristol, L. Jin, R.W. Kuncl, Y. Kanai,
M.A. Hediger., Y. Wang, J.P. Schielke,
F.D. Weltry: Knock out of glutamate transporters
reveals a major role for astroglial transport in
excitotoxicity and clearance of glutamate.
Neuron 16:675-686, 1996.<br><br>
Scorer C.A.: Preclinical and clinical challenges in
the development of disease-modifying therapies
for Alzheimer�s disease. Drug Discovery
Today 6:1207-1219, 2001.<br><br>
Sramek J.J. and N.R. Cutler: Recent developments
in the drug treatment of Alzheimer�s disease.
Drug and Aging 14:359-373, 1999.<br><br>
Xu H., G.K Gouras, J.P. Greenfield: Estrogen
reduces neuronal generation of Alzheimer
beta-amyloid peptides. Nature Med. 4:447-451,
1998.
<br>
</td>
<td valign=top align=left bgcolor=silver>
<a name="cited"><b>CITED</b></a>
<br><br>
<small>
Patocka J, Slaninova J, Kunesova G: Neuroprotective peptides as drug candidates against Alzheimer's disease. J Appl Biomed 3:67-73, 2005.
</small>
</td>
</tr>
</table>
<br>
<a href="http://www.zsf.jcu.cz/jab">BACK</a>
</body>
</html>
nieoullon_ad-old.htm